Oncology Letters最新文献_第6页

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review). 关于决定肿瘤细胞命运的吞噬调节因子 CD47 的癌症研究进展（综述）。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-09 DOI: 10.3892/ol.2024.14389

Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang

{"title":"Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).","authors":"Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang","doi":"10.3892/ol.2024.14389","DOIUrl":"https://doi.org/10.3892/ol.2024.14389","url":null,"abstract":"Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma. Upregulation of CD47 expression facilitates the growth of numerous types of tumor cells, while downregulation of its expression promotes phagocytosis of tumor cells by macrophages, thereby limiting tumor growth. In addition, blocking CD47 activates the cyclic GMP-AMP (cGAMP) synthase/cGAMP/interferon gene stimulating factor signaling pathway and initiates an adaptive immune response that kills tumor cells. The present review describes the structure, function and interactions of CD47 with its ligands, as well as its regulation of phagocytosis and tumor cell fate. It summarizes the therapeutics, mechanisms of action, research advances and challenges of targeting CD47. In addition, this paper provides an overview of the latest therapeutic options for targeting CD47, such as chimeric antigen receptor (CAR) T-cells, CAR macrophages and nanotechnology-based delivery systems, which are essential for future clinical research on targeting CD47.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"5 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140636740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer. 非小细胞肺癌中C群色素痣和IFN-γ的临床预后意义

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-09 DOI: 10.3892/ol.2024.14392

Yongming Wang, Weiyu Wang, Huaijie Wang, Liya Qin, Meijia Zhang, Yong Zhang, Yubing Wang, Changcheng Hao, Meihua Qu, Gongchao Wang

{"title":"Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer.","authors":"Yongming Wang, Weiyu Wang, Huaijie Wang, Liya Qin, Meijia Zhang, Yong Zhang, Yubing Wang, Changcheng Hao, Meihua Qu, Gongchao Wang","doi":"10.3892/ol.2024.14392","DOIUrl":"https://doi.org/10.3892/ol.2024.14392","url":null,"abstract":"Lung cancer is the most common cancer in the world due to its high incidence and recurrence. Genetic instability is one of the main factors leading to its occurrence, development and poor prognosis. Decreased xeroderma pigmentosum group C (XPC) expression notably enhances the stem cell properties of lung cancer cells and increases their proliferation and migration. Additionally, patients with lung cancer and low XPC expression had a poor prognosis. The purpose of the present study was to analyze the effect of XPC and IFN-γ on the clinical prognosis of patients with non-small cell lung cancer (NSCLC). Lung adenocarcinoma specimens were collected from a total of 140 patients with NSCLC. Additionally, from these 140 patients, 48 paracarcinoma tissue specimens were also collected, which were later used to construct tissue microarrays. The expression of XPC and IFN-γ in cancer tissues and in paraneoplastic tissues was detected using immunohistochemistry. The prognosis and overall survival of patients were determined through telephone follow-up. The results showed a positive correlation between expression of XPC and IFN-γ in NSCLC. Additionally, high expression of both markers was associated with a favorable prognosis in patients with NSCLC. The aforementioned findings suggest that the expression of XPC and IFN-γ has prognostic value in clinical practice and is expected to become a marker for clinical application.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"40 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140636746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] Tremella polysaccharides inhibit cellular apoptosis and autophagy induced by Pseudomonas aeruginosa lipopolysaccharide in A549 cells through sirtuin 1 activation. [撤稿】震颤菌多糖通过激活sirtuin 1抑制铜绿假单胞菌脂多糖在A549细胞中诱导的细胞凋亡和自噬。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-08 DOI: 10.3892/ol.2024.14384

Xiaolan Shi, Wenfeng Wei, Ning Wang

引用次数: 0

Prognostic value of serum tartrate‑resistant acid phosphatase‑5b for bone metastasis in patients with resectable breast cancer. 可切除乳腺癌患者血清抗酒石酸磷酸酶-5b对骨转移的预后价值

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-05 DOI: 10.3892/ol.2024.14383

Masafumi Shimoda, Yasufumi Sato, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu

{"title":"Prognostic value of serum tartrate‑resistant acid phosphatase‑5b for bone metastasis in patients with resectable breast cancer.","authors":"Masafumi Shimoda, Yasufumi Sato, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu","doi":"10.3892/ol.2024.14383","DOIUrl":"https://doi.org/10.3892/ol.2024.14383","url":null,"abstract":"Bone metastasis significantly affects the quality of life of patients with metastatic breast cancer, and can shorten overall survival. Identifying patients with early-stage breast cancer at high risk for bone metastasis and preventing bone metastasis may lead to a better quality of life and prolonged survival. The present study investigated whether serum tartrate-resistant acid phosphatase-5b (TRACP-5b), a bone turnover marker, can be a prognostic factor for bone metastasis. Female patients who underwent resectable breast surgery between May 2002 and August 2006 were consecutively investigated. A total of 304 patients with a median follow-up of 3,722 days were retrospectively analyzed. TRACP-5b levels in sera prepared from patients' blood drawn preoperatively without any presurgical treatments were measured using an enzyme-linked immunosorbent assay. The cutoff of TRACP-5b levels, in order to separate patients into high and low TRACP-5b groups, was set at median (347 mU/dl). The associations of clinicopathological factors, including TRACP-5b, with bone metastasis-free interval (BMFI), which was defined as the duration between surgery and the diagnosis of bone metastasis at any time point, were examined. Multivariate analysis of various clinicopathological features revealed that lymph node metastasis and histological grade were independent factors associated with BMFI (P=0.017 and 0.030, respectively). In patients with node-positive breast cancer (n=114), a high TRACP-5b level and a high grade were significantly and independently associated with worse BMFI (log-rank P=0.041 and 0.011, respectively). In conclusion, these findings indicated that TRACP-5b may predict bone metastasis in patients with node-positive breast cancer.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"12 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140627777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastasis to the bladder from primary breast cancer: A case report and literature review. 原发性乳腺癌转移至膀胱：病例报告和文献综述。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-05 DOI: 10.3892/ol.2024.14382

Hanli Zhou, Danna Liu, Lu Chen, Yujie Zhang, Xiaoli Zhao, Yongchao Ge, Mengmeng Liu, Tiandong Kong

{"title":"Metastasis to the bladder from primary breast cancer: A case report and literature review.","authors":"Hanli Zhou, Danna Liu, Lu Chen, Yujie Zhang, Xiaoli Zhao, Yongchao Ge, Mengmeng Liu, Tiandong Kong","doi":"10.3892/ol.2024.14382","DOIUrl":"https://doi.org/10.3892/ol.2024.14382","url":null,"abstract":"Breast cancer is the most prevalent malignant tumor affecting women and represents the leading cause of female cancer-related mortality worldwide. Although distant organ metastasis accounts for the majority of breast cancer-related deaths, reports on bladder metastasis are limited in the existing literature. The present study describes the case of a patient with bladder metastasis originating from breast cancer. In addition, the present study also provides a review of 54 cases of similar disease that have been documented in the currently available literature. The literature review aims to elucidate the clinicopathological characteristics and therapeutic approaches for such conditions. The median time from breast cancer diagnosis to bladder metastasis was found to be 5.6 years (range, 0-28 years). The origin of the bladder metastases was predominantly invasive ductal carcinoma (IDC) accounting for 52.3% of cases, followed by invasive lobular carcinoma, accounting for 40.9% of cases. The pathology in the primary tumor was the same as the pathology of the bladder metastases in all cases. There was an 88.9% concordance rate for estrogen receptor status, while the progesterone receptor status was 83.3% and the human epidermal growth factor receptor 2 expression status was 100%. The primary initial symptoms included urinary system manifestations, such as increased frequency, urgency, dysuria, urinary incontinence, nocturia and gross hematuria. For the cystoscopic examination, the predominant findings were bladder wall thickening or masses, along with ureteral orifice masses. Overall, the present study demonstrated that the occurrence of bladder metastasis often follows the metastasis of other organs, with IDC being the most prevalent subtype. The pathological characteristics between the primary tumor and bladder metastasis exhibit a high degree of concordance.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"16 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140627868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of combined use of ribociclib with PARP1 inhibitor on cell kinetics in breast cancer. 联合使用 ribociclib 和 PARP1 抑制剂对乳腺癌细胞动力学的影响

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-03 DOI: 10.3892/ol.2024.14376

Ercan Pulat, Mehmet R Topçul

引用次数: 0

Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis. 化疗后巩固免疫检查点抑制剂治疗不可切除的局部晚期 PD-L1 阴性非小细胞肺癌的疗效：系统综述与荟萃分析。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-03 DOI: 10.3892/ol.2024.14375

Sunyin Rao, Li Min, Jie Zhao, Juan Su, Lianhua Ye

{"title":"Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis.","authors":"Sunyin Rao, Li Min, Jie Zhao, Juan Su, Lianhua Ye","doi":"10.3892/ol.2024.14375","DOIUrl":"https://doi.org/10.3892/ol.2024.14375","url":null,"abstract":"Chemoradiotherapy (CRT) followed by consolidation of immune checkpoint inhibitors (ICIs), such as durvalumab or pembrolizumab, for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with tumor PD-L1 expression <1% remains a topic of controversy. Previous studies from PubMed, Cochrane Library and Embase databases were searched for a meta-analysis. A total of 16 studies were included in part one of the meta-analysis and it was observed that consolidation of ICIs after CRT improved overall survival (OS) [hazard ratio (HR) 1.46; P=0.005] and progression-free survival (PFS) (HR 1.26; P=0.023) for the patients with PD-L1 expression ≥1% compared with those with PD-L1 expression <1%. Then, 15 studies were included in part two of the meta-analysis and the results indicated that the pooled 1, 2 and 3-year OS were 77% vs. 83% (P=0.07), 55% vs. 59% (P=0.327) and 38% vs. 51% (P=0.006) for CRT alone compared with CRT followed by consolidation of ICIs, respectively. The pooled 1, 2 and 3-year PFS were 51% vs. 53% (P=0.632), 29% vs. 40% (P=0.015) and 20% vs. 28% (P=0.153) for CRT alone compared with CRT followed by consolidation of ICIs, respectively. The findings of the present study highlighted that the benefits of CRT followed by consolidation of ICIs were higher compared with CRT alone in patients with unresectable, locally advanced NSCLC and PD-L1 expression <1%. Consolidation of ICIs after CRT would provide greater benefits for locally advanced NSCLC patients with PD-L1 expression ≥1% compared with those with PD-L1 expression <1%.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: [Corrigendum] miR‑137 suppresses proliferation, migration and invasion of colon cancer cell lines by targeting TCF4. 勘误：[更正] miR-137 通过靶向 TCF4 抑制结肠癌细胞系的增殖、迁移和侵袭。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-03 DOI: 10.3892/ol.2024.14378

Wei-Ping Bi, Min Xia, Xin-Jian Wang

引用次数: 0

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases. 肿瘤溶解病毒疗法可刺激抗肿瘤免疫反应，对晚期肉瘤具有活性：两个病例的报告。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-03 DOI: 10.3892/ol.2024.14377

Yeting Qiu, Aijun Qin, Ronghua Zhao, Jun Ding, William Wei-Guo Jia, Manu Singh, Yanal Murad, Qian Tan, Ganessan Kichenadasse

{"title":"Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases.","authors":"Yeting Qiu, Aijun Qin, Ronghua Zhao, Jun Ding, William Wei-Guo Jia, Manu Singh, Yanal Murad, Qian Tan, Ganessan Kichenadasse","doi":"10.3892/ol.2024.14377","DOIUrl":"https://doi.org/10.3892/ol.2024.14377","url":null,"abstract":"Sarcoma is derived from mesenchymal neoplasms and has numerous subtypes, accounting for 1% of all adult malignancies and 15% of childhood malignancies. The prognosis of metastatic or recurrent sarcoma remains poor. The current study presents two cases of sarcoma enrolled in a phase I dose escalation trial for solid tumor, who had previously failed all standard therapies. These patients were treated with VG161, an immune-stimulating herpes simplex virus type 1 oncolytic virus with payloads of IL-12, IL-15 and IL-15 receptor α unit, and a programmed cell death 1 (PD-1)/PD-1 ligand 1 blocking peptide. Both cases demonstrated stable disease as the best response, accompanied by a noteworthy prolongation of progression-free survival (11.8 months for chondrosarcoma and 11.9 months for soft tissue sarcoma, respectively) at a dose of 2.5×10<sup>8</sup> PFU/cycle. In addition, the treatment led to the activation of anti-cancer immunity, as evident from cytokine, lymphocyte subset and related pathway analyses of peripheral blood and/or tumor biopsy samples. These promising results suggest that VG161 monotherapy holds promise as an effective treatment for sarcoma and warrants further investigation through clinical trials. The two reported patients were part of a phase I clinical trial conducted and registered on the Australian New Zealand Clinical Trials Registry in Australia (registration no. ACTRN12620000244909; registration date, 26 February, 2020).","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"2 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140627469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report. 埃洛珠单抗、泊马度胺和地塞米松联合疗法成功治疗达拉单抗耐药的多发性骨髓瘤髓外疾病：病例报告。

IF 2.9 4区医学

Oncology Letters Pub Date : 2024-04-03 DOI: 10.3892/ol.2024.14381

Masataka Sakashita, Naohi Sahara, Jun Aoki, Takashi Matsunaga, Seiichiro Kobayashi, Shinsuke Kitahara, Tomoki Fujii, Nobuhiro Ohno

{"title":"Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report.","authors":"Masataka Sakashita, Naohi Sahara, Jun Aoki, Takashi Matsunaga, Seiichiro Kobayashi, Shinsuke Kitahara, Tomoki Fujii, Nobuhiro Ohno","doi":"10.3892/ol.2024.14381","DOIUrl":"https://doi.org/10.3892/ol.2024.14381","url":null,"abstract":"Despite the emergence of monoclonal antibodies, the prognosis of patients with multiple myeloma (MM) with extramedullary disease remains poor. The present report describes a rare case of daratumumab-refractory MM that was successfully treated with elotuzumab, pomalidomide and dexamethasone. A 66-year-old male patient diagnosed with MM was treated with bortezomib, lenalidomide and dexamethasone, followed by high-dose chemotherapy and autologous stem cell transplantation. Thereafter, the patient was treated with lenalidomide and dexamethasone as maintenance therapy. This was changed to daratumumab, bortezomib and dexamethasone when new paraskeletal lesions were identified, resulting in marked tumor shrinkage. After 15 months, an increase in serum monoclonal protein levels, development of a skeletal lesion in the right second rib and extramedullary disease of the right thoracic mediastinal lymph nodes were noted. Treatment with elotuzumab, pomalidomide and dexamethasone (EPd) resulted in expeditious symptomatic improvement and regression of the lesions. Notably, during daratumumab, bortezomib and dexamethasone treatment, lymphocyte counts gradually increased to a level at which elotuzumab was sufficiently effective. EPd might be a promising strategy for the treatment of patients with relapsed extramedullary MM while on daratumumab treatment.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"24 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140627584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0